Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

Summary: Dyslipidemia is a risk factor for cardiovascular disease (CVD), a major cause of death worldwide. Angiopoietin-like protein 3 (ANGPTL3), recognized as a new therapeutic target for dyslipidemia, regulates the metabolism of low-density lipoprotein-cholesterol (LDL-C) and triglycerides. Here,...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirotaka Fukami, Jun Morinaga, Hironori Nakagami, Hiroki Hayashi, Yusuke Okadome, Eiji Matsunaga, Tsuyoshi Kadomatsu, Haruki Horiguchi, Michio Sato, Taichi Sugizaki, Takashige Kuwabara, Keishi Miyata, Masashi Mukoyama, Ryuichi Morishita, Yuichi Oike
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
ANGPTL3
peptide vaccine
dyslipidemia
atherosclerosis
fatty liver
triglyceride
Medicine (General)
R5-920
Online Access:https://doaj.org/article/e98668609cb34bd8a3fd098985594146
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items